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The aim of this study was to investigate cytokine release from oral keratinocytes and ﬁbroblasts in response to AM and short-
ened derivatives previously characterised in terms of their antimicrobial activities. Cells were incubated with AM or its fragments
(residues1-12,1-21,13-52,16-21,16-52,22-52,26-52,and34-52),andculturesupernatantscollectedafter1,2,4,8,and24hours.
A time-dependant increase in production of interleukin1-α and interleukin 1-β from keratinocytes in response to all peptides was
demonstrated. However, exposure to fragments compared to whole AM resulted in reduced production of these cytokines (60%
mean reduction at 24 hours, P<. 001). No consistent diﬀerences were shown between the cytokine response elicited by antimi-
crobial and nonantimicrobial fragments. The production of interleukin-6 and interleukin-8 did not change signiﬁcantly with time
or peptide used. Fibroblast cells were relatively unresponsive to all treatments. This study demonstrates that antimicrobial activity
does not predict cytokine response to adrenomedullin or its shortened derivatives.
Copyright © 2007 Quratul Ann Hussain et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. INTRODUCTION
Adrenomedullin (AM) is a 52 amino acid multifunctional
peptide [1] produced by a wide variety of tissues and cells.
Previous studies have demonstrated that AM has antimicro-
bial activity against a number of members of the normal
skin, oral, respiratory tract, and gut microﬂora [2]. Carboxy-
terminalfragments(residues13-52,16-52,22-52,and34-52)
of AM have been shown to be up to 250-fold more active
than the parent molecule in terms of antimicrobial activity.
Whereas, AM fragments (1-12, 1-21, 16-21, and 26-52) were
foundtobeinactive[3].Furthersupportforaroleinhostde-
fence has been provided by a study to demonstrate that pro-
tein and mRNA levels are increased when oral keratinocytes
are exposed to whole bacteria and culture supernatants [4].
It is also recognised that AM inﬂuences the inﬂamma-
tory response to infection. The regulation by AM of cy-
tokine production from cultured rat macrophages in re-
sponse to lipopolysaccharide (LPS) has been previously in-
vestigated [5, 6]. AM was shown to signiﬁcantly reduce
LPS-induced TNF-α production by macrophages. In con-
trast, AM up-regulated the production of the cytokine IL-
6 in both LPS-stimulated and unstimulated macrophages.
Other ﬁndings also support the role of AM as a proinﬂam-
matory factor, with both migratory inhibitory factor (MIF)
and IL-1β signiﬁcantly increased in the presence of AM [6].
These somewhat conﬂicting results emphasise the complex-
ity of the interactions between AM and the inﬂammatory
system.
Postsecretory processing of the cathelicidin LL-37 pep-
tide has been shown to generate fragments with enhanced
antimicrobial activity and a marked decrease in their ability
tostimulateIL-8productionfromculturedkeratinocytes[7].
It is also known that structural modiﬁcations of defensins
havesigniﬁcanteﬀectsonbothchemotacticfunctionandan-
timicrobial activity [8]. Thus it is hypothesised that postse-
cretory processing of the AM molecule may generate mul-
tiple shortened derivatives with enhanced antimicrobial ac-
tivity but with signiﬁcantly reduced proinﬂammatory activ-
ity. The aim of this study was to investigate cytokine release
from oral keratinocyte and ﬁbroblast cells in response to AM
and eight fragments of the parent molecule, that were previ-
ously characterised in terms of their antimicrobial activities
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2. MATERIALS AND METHODS
2.1. Celllines
Cell lines used were FIB originally derived from adult
oral gingival keratinocytes, and human gingival ﬁbroblasts
(HGF) derived from the oral mucosa [9]. Dulbecco’s Mod-
iﬁed Eagle’s Medium (DMEM), containing 10% foetal calf
serum and penicillin/streptomycin, was used to culture cells.
Cells were seeded into 96-well microtitre plates and when
90% conﬂuent, were rendered quiescent by placing them in
serum-starved medium for 24 hours prior to peptide expo-
sure.
2.2. Peptides
SyntheticAMandAMfragments(residues1-12,1-21,13-52,
16-21, 16-52, 22-52, 26-52, and 34-52) were purchased from
Phoenix Pharmaceuticals (Karlsruhe, Germany).
AM fragment positions in the AM molecule are shown as
follows:
YRQSMNNFQGLR12S13FGC16RFGTC21T22VQKL26AH
QIYQFT34DKDKDNVAPRSKISPQGY52
2.3. Doseandtimeresponseexperiments
AM and its fragments diluted in PBS to provide concentra-
tions of 10−6,1 0 −7,1 0 −8,a n d1 0 −9 g/mL were used to de-
termine the eﬀect of concentration on cytokine response to
these peptides. Cells were exposed to the four concentrations
and supernatants were collected after 24 hours. Untreated
c e l l sw e r eu s e da sn e g a t i v ec o n t r o l s( c e l l si n c u b a t e dw i t h o u t
AM or fragments). ELISAs (R & D Systems) were performed
to measure interleukin 1-α (IL-1α), interleukin 1-β (IL-β),
interleukin-6 (IL-6), and interleukin-8 (IL-8) levels.
AM and its fragments diluted in PBS at a concentration
of 10−9 g/mL were used for time response experiments. Cells
were exposed to AM and fragments, and supernatants col-
lected at 1, 2, 4, 8 and 24 hours. ELISAs were then performed
to measure IL-1α,I L - β, IL-6, and IL-8 levels. Untreated cells
were used as negative controls.
2.4. MTTcellproliferationassay
Cells were plated in 96-well ﬂat-bottomed plates in 200μLo f
medium and incubated overnight. Cells were serum-starved
for 24 hours and then incubated with AM or fragments at a
concentration of 10−6 g/mL. After 24 hours, 100μLo ff r e s h
medium was added into each well, together with 100μLo f
5mg/mL of MTT, and incubated for 2 hours. Media were
then aspirated and 200μLo fD M S Ow a sa d d e df o r1 5m i n -
utes.Plateswerethenreadinaspectrophotometerat595nm.
2.5. Statistics
Results were analysed using two-way ANOVA and Bonfer-
roni post tests (Prism 4 software).
3. RESULTS
3.1. MTTcellproliferationassay
Using the MTTassay with HGF cells, it was shown that treat-
ment with AM or its fragments resulted in no signiﬁcant de-
crease in viability or stimulation of the cells. Likewise, with
FIB cells, treatment with AM or its fragments demonstrated
no signiﬁcant eﬀect.
3.2. Doseresponseassay
The eﬀect of AM and its fragments on cytokine production
was shown not to be signiﬁcantly dose dependent over the
physiological range 10−6 to 10−9 g/mL. A ﬁnal concentration
of 10−9 g/mL was selected for further experiments.
3.3. Cytokineresponseofgingivalﬁbroblasts
Cells were exposed to AM and individual fragments at a con-
centration of 10−9 g/mL. No signiﬁcant increase of either IL-
1α or IL-1β was observed over 24 hours or between the re-
sponses elicited by the whole molecule and its fragments (<
3pg/mL in all cases). IL-6 and IL-8 were produced by the
cells; however levels did not change signiﬁcantly with either
time or peptide tested (all levels < 140pg/mL).
3.4. Cytokineresponseofgingivalkeratinocytes
Cells were exposed to AM and individual fragments at a con-
centration of 10−9 g/mL. A time-dependent increase in the
release of IL-1α and IL-1β with exposure to AM and eight
shortened derivatives was observed. Treatment with AM re-
sulted in a signiﬁcant increase in IL-1α and IL-1β at 4 hours
(P<.001 and P<.05, resp.), 8 hours (P<.001), and 24
hours (P<.001) in comparison to controls. Treatment with
all fragments resulted in a signiﬁcant increase in both IL-1α
and IL-1β at 24 hours (P<.001) in comparison to controls.
Signiﬁcant increases were also observed at 8 hours with the
exception of the IL-1α response to fragment 1-12 and the IL-
1β responses to fragments 1-12, 1-21, and 22-52. All frag-
ments showed a signiﬁcantly decreased response for both cy-
tokinesincomparisontothewholemoleculeatboth8hours,
with the exception of the IL-1α response to fragment 1-12,
and 24 hours (60% overall mean reduction, P<.001). Re-
sponsesat24hourstoAMandindividualpeptidesareshown
in Figures 1 and 2. No consistent diﬀerences were demon-
strated between the cytokine response elicited by the antimi-
crobial and nonantimicrobial fragments. IL-6 and IL-8 were
produced by the cells; however, levels did not change signiﬁ-
cantly with time or peptide tested (all levels < 140pg/mL).
4. DISCUSSION
Keratinocytes isolated from the skin synthesize and release
the inﬂammatory cytokines IL-1, IL-6, and IL-8 in response
toLPS,bacterialproducts,andotherinﬂammatorycytokines
[10]. In contrast, IL-1 is found in the intracellular com-
partment of ﬁbroblasts but is not actively secreted [11].
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Figure 1: IL-1α response of FIB cells after a 24-hour exposure to
AM and fragments (mean ± SD; n = 6). AM and individual frag-
ments were each added to cultured cells at a ﬁnal concentration of
10−9 g/mL. Antimicrobial fragments (16-52, 22-52, 34-52, and 13-
52). Nonantimicrobial fragments (26-52, 16-21, 1-12, and 1-21).
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Figure 2: IL-1β response of FIB cells after a 24-hour exposure to
AM and fragments (mean ± SD; n = 6). AM and individual frag-
ments were each added to cultured cells at a ﬁnal concentration of
10−9 g/mL. Antimicrobial fragments (16-52, 22-52, 34-52, and 13-
52). Nonantimicrobial fragments (26-52, 16-21, 1-12, and 1-21).
stimulation, IL-6 has been shown to be produced from skin
keratinocytes [12] and from Swiss 3T3 mouse ﬁbroblast cells
[13]. AM was found to stimulate basal secretion of IL-6 5.5-
fold from Swiss 3T3 cells, while other peptides including AM
(22-52) had much weaker stimulatory eﬀects. The cytokine
response of the oral keratinocytes and ﬁbroblasts to AM in
this study supports these ﬁndings.
AM binds to both speciﬁc AM and CGRP receptors and
these are often expressed together in cells. The use of cur-
rentlyavailableinhibitorscanhelptodeﬁnewhichreceptoris
actually mediating an eﬀect. In terms of peptide-receptor in-
teraction and activation of speciﬁc signal transduction path-
ways with ﬁbroblasts cells, the eﬀe c to fA Mo nI L - 6s e c r e t i o n
from Swiss 3T3 cells has been shown to be inhibited by the
AM-receptorantagonistAM(22-52)andacAMP-dependent
protein kinase inhibitor [13]. IL-1α and IL-6 release from
oral keratinocytes, in response to AM, has been shown to be
inhibited by AM (22-52) but not by the CGRP (8-37) an-
tagonist (Hagi-Pavli, unpublished observations). It is known
that the C-terminal section of the AM molecule binds to the
receptorwithgreatestaﬃnity[1].Inthecurrentstudy,theC-
terminal fragments generally elicited a higher IL-1α and IL-
1β response than the N-terminal fragments. Further studies,
to fully determine the receptor binding characteristics and
signal transduction pathway(s) activated by shortened AM
derivatives, are required.
Recently, it has been shown that the cationic antimicro-
bial peptide cathelicidin LL-37, found on the skin surface, is
shortened by a serine protease-dependant mechanism into
novel antimicrobial peptides with enhanced antimicrobial
action but reduced proinﬂammatory activity [7]. It is sug-
gested that, from the single human cathelicidin gene, multi-
ple products are potentially generatedwith a range of biolog-
icalactivities,eachrelevanttothelocalenvironmentinwhich
they are released. The degradation of AM by host plasma
membrane enzymes to major degradation products of 2-52
and 8-52, with smaller amounts of 26-52, 27-52, 28-52, and
33-52 [14], has been demonstrated. In a similar study [15],
degradation of AM by matrix metalloproteinase-2 to frag-
ments of 8-52, 11-52, 23-52, 29-52, 11-28, and 11-22 has also
been shown. Thus postsecretory processing may generate up
to 12 diﬀerent shortened derivatives of AM as shown in these
in vitro studies. The current study investigated the cytokine
response to eight fragments that have been previously char-
acterised in terms of their antimicrobial and vascular activi-
ties [3]. Further studies with other AM fragments that could
possibly be generated in vivo, to further examine a possible
relationship between antimicrobial and inﬂammatory activ-
ities, are warranted.
This study showed a clear diﬀerence in the potential im-
munomodulatory responses when oral keratinocytes were
exposed to either AM or shortened derivatives of the par-
ent molecule. These observations support previous studies
in several cell, animal and human, systems that AM has both
antimicrobial properties and also acts as a host stimulatory
molecule. Peptide secretion followed by its processing could
enable the epithelia to further modify the spectra of biolog-
ical activity and regulate the balance between host immune
modulation and inhibition of microbial growth.
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